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Abstract
Background/Aims: The association between postoperative infection and prolonged survival in 
high-grade glioma is still a matter of debate. Previously we demonstrated that the intracerebral 
(i.c.) injection of heat-inactivated staphylococcal epitopes (HISE) resulted in a well-defined 
influx of immunocompetent cells across the blood-brain barrier. The present study investigated 
the potential antitumoral effect of HISE-immunostimulation in an experimental glioma model. 
Methods: Wistar rats were intracerebrally implanted with 9L gliosarcoma cells (n=6), 9L cells 
mixed with HISE (n=12), or phosphate buffered saline (n=4). Tumor growth was measured by 
serial magnetic resonance imaging (MRI). After death due to the tumor burden, the brains were 
histopathologically assessed for inflammation and oncolysis. A toxicity assay was performed to 
quantify potential impairment of HISE on tumor cell growth in vitro. Results: Animals treated 
by HISE showed a significant increase in average survival and even complete regression of 
an already established mass in one case. Naïve 9L gliosarcomas failed to recruit significant 
numbers of systemic immune cells. In contrast, concomitant intracerebral HISE inoculation 
lead to a oncolysis and a distinct peri- and intratumoral infiltration of macrophages, CD8 and 
CD4 co-expressing T-lymphocytes in two thirds of the tumor-bearing animals. The toxicity 
screening showed HISE-mediated oncolysis to be ineffective ex vivo. Conclusion: This study 
describes a novel approach for combatting malignant glioma using inactivated staphylococci 
as potent immunomodulators. Our results provide an outline for investigating the strategic 
potential of bacteria as emerging future therapeutics.
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IntroductionDespite advances in surgical techniques, radio- and chemotherapy, the outcome of patients suffering from glioblastoma multifomre (GBM) remains poor with a median 
survival of less than 15 months [1]. Whereas the diffuse infiltration of malignant gliomas considerably limits the results of surgical treatment and irradiation, the success of chemo- or receptor-based therapies are restricted by the heterogeneity of glioblastoma surface antigens. Considering the limited effects of current standard treatments, immunotherapeutic strategies are appealing, since stimulated immune effector cells may attack even tumor cells located in areas inaccessible to surgery, chemo- or radiation therapy [2-4].However, without therapeutic reinforcement, the host´s glioma-directed immune response is hardly effective for several reasons. One reason for the almost exclusive growth of malignant gliomas within the central nervous system (CNS) is their segregation from the systemic immunosurveillance beyond the blood-brain barrier in early tumor growth. Furthermore, GBM escape from an immunogenic response by the release of immunosuppressive cytokines [5, 6], downregulation of MHC class I molecules [7], activating Fas-mediated apoptosis of T-cells [8] and other mechanisms. Therefore, different immunological treatments have been designed to enhance the intrinsic antitumor response 
that include antibodies targeting tumor-specific antigens [9], vaccination with dendritic cells 
(DC) [9], adoptive transfer of ex vivo activated immune cells with cytolytic properties [10] or boosting endogenous cell-mediated immunity by immunostimulatory adjuvants (ISA) [2]. The latter immunotherapeutic approach is supported by the clinical observation, that postoperative infections within or near the tumor site might have promoted a prolonged survival or even complete remission in several GBM patients [11-15]. Recently these 
anecdotal findings were substantiated by the results of two retrospective single-center 
studies, one demonstrating a significant correlation between postoperative infection and survival advantage [16] and the other showing a trend towards a prolonged survival in 
patients harboring infections in the tumor resection bed in contrast to those with superficial infections [17]. The only study systematically investigating the therapeutic potential of living bacteria to enhance antitumor immunity in GBM reported disastrous effects. By intracarotid injection of spores from the nonpathogenic germ Clostridium butyricum in GBM-patients, the malignant mass converted into a putrid abscess within one week that was then operated on. However, one third of the patients died due to a fulminant brain abscess formation caused by a rapid and uncontrollable growth of the bacterial agents [18]. Recently we have demonstrated that the proliferative capacity of Staphylococcus (S.) 
epidermidis and other bacteria could be effectively eliminated by heat-inactivation while maintaining its immunostimulatory properties. Intracerebral (i.c.) injection of inactivated 
staphylococci into Wistar rats caused a rapid and sustained influx of various systemic immunocompetent cells into the CNS in a reproducible timecourse including, among others, macrophages and CD8+ cytotoxic T-lymphocytes. Moreover, the inflammation was locally restricted to the site of the deposit of the inactivated bacteria, and all experimental animals 
tolerated the procedure well without signs of cerebral infection [19]. 
Based on these findings, the specific aim of our study was to investigate if such a distinct intracerebral immune cell recruitment induced by inactivated staphylococci could affect tumor growth in an experimental gliosarcoma model and to shed light on the potential mechanisms by which systemic leucocytes combat malignant glioma.
Materials and MethodsAll animal experiments in this study were conducted according to the German law for the welfare of animals and approved by the regional committee on animal ethics (Landesamt für Natur, Umwelt- und 
Verbraucherschutz Nordrhein-Westfalen, file reference of ethical vote: 9.93.2.10.31.07.305).
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Cultivation and inactivation of bacteria
S. epidermidis (strain RP62A) were cultivated in soybean-casein digest broth (Trypticase™ Soy Broth, 
Becton Dickinson, Heidelberg, Germany) at 37°C for 16 h on a rotary shaker (Bühler™ Shakers, Hechingen, Germany) and concentrated up to 1010 colony forming units (cfu)/ml in phosphate buffered saline (PBS). 
The concentration was determined by counting in a Neubauer-chamber and confirmed by serial plating. 
Next, bacteria were inactivated at 65°C for 1 h in a water bath. Both inactivation of the bacteria and sterility 
of the working conditions were verified by plating the stock solution of the heat-inactivated bacteria prior to and after taking out the volumes required for the subsequent experiments.
Tumor cell culture
The 9L gliosarcoma cell line was maintained in Dulbecco´s modified Eagle medium (DMEM) High Glucose supplemented with 5% fetal calf serum Gold (FCS) (PAA Laboratories, Cölbe, Germany) and 
penicillin-streptavidin in a humidified atmosphere of 5% carbon dioxide at 37°C. The cells were grown to 
confluence and harvested with trypsin. Cell viability before implantation was estimated by a Trypan blue 
exclusion test. After determination of the exact concentration by counting in a Neubauer-chamber, the 9L cells were washed twice in endotoxin-free PBS and then adjusted to the concentration required for the following experiments.
In vitro toxicity screening 
The 9L cell lines were plated at a density of 105 cells/ml in DMEM. Three dishes of heat-inactivated 
S. epidermidis (HISE) were plated for each concentration and three further dishes used as controls. The 9L cells were grown for 24 hours. Thereafter, the medium was removed and replaced by medium containing the concentrations 105/ml or 6x107/ml or 6x109/ml of HISE particles, respectively, hence outnumbering 
the HISE to 9L-ratio of 1:1 used in the injection experiments hundred- to ten-thousand-fold. Pure medium 
instead of HISE was used in controls. The dishes were incubated for another 5 days, and cells were counted 
to estimate any impairment of tumor cell growth by HISE in vitro.
Animal preparation and operative procedures
All experimental animal protocols were performed under sterile conditions using a laminar air flow 
bench. For the i.c. injection, HISE and 9L cells were mixed to a concentration of 4x106 HISE particles and 4x106 9L cells per ml in PBS. Control animals received an equal concentration of only 9L cells in PBS, or 
pure PBS. 22 male Wistar rats (in-house breeding of the University of Cologne) weighing 350-450g were 
anesthetized by intraperitoneal injection of ketamine hydrochloride (Ketavet™, Pfizer Co., Karlsruhe, Germany) and xylazine hydrochloride (Rompun™, Bayer Vital Co., Leverkusen, Germany), and placed in a stereotactic frame (Stoelting-Instruments, Wood Dale, IL, USA). After midline incision of the scalp, a 0.006 
inch burr hole was placed on the right calvaria 1 mm anterior and 3 mm lateral to the bregma, and a volume 
of 25 μl of the respective stock solution was administered 6 mm deep into the right striatum by means of convection-enhanced delivery using a programmable syringe pump (Harvard apparatus™ PHD 22/2000, 
Holliston, MA, USA) at an injection velocity of 1 μl/min. After injection, the needle was kept in place for 
5 min to minimize backflow and eventually withdrawn at a rate of 1 mm/min thereafter. Finally, the burr hole was sealed with bone wax, and the skin closed with sutures. Following surgery, the animals were kept under a 12h dark/light-cycle with free access to food and water and were monitored daily for alertness, signs of discomfort or the presence of neurological abnormalities. Altogether n=12 animals received 105 
9L cells mixed with 105 HISE particles in 25 μl of PBS (HISE-group), n=6 received 105 9L cells in 25μl of PBS 
(9L-group), and n=4 received 25 μl of PBS. 
MR imaging and tumor volumetryMagnetic resonance (MR) images were obtained with a clinical scanner (Philips Achieva 1.5 t, Philips 
Healthcare, Best, The Netherlands) using a 2.3 cm micro ring-coil on days 13 / 19 / 25 / 32 / 40 and 61 post 
injection (p.i.). 250 μm MR slices were obtained in the following sequence: coronal and sagittal noncontrast T1-weighted images, T2-weighted images, and T1-weighted images 20 minutes after intraperitoneal 
administration of 1 ml Omniscan™ 0.5 mmol/ml (GE Healthcare Buchler, Braunschweig, Germany), a gadolinium-based contrast agent. Tumor volumes were calculated on the basis of the T1-weighted images 
with contrast media by using the stereotactic treatment planning software STP* 3.5 (Stryker-Leibinger, Freiburg, Germany).        
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Tissue preparation
The tumor-bearing animals died either spontaneously or were sacrificed in case of severe tumor-associated symptoms (i.e., if they were no more able to eat and drink) by an intraperitoneal injection of 
an overdose of ketamine and xylazine, and perfused with 100 ml of 0.1 mol/l cold PBS (pH 7.4, 4°C). The brains were removed, cut coronally at the injection site, immersed in a cryoprotective medium (Tissue-
Tek™, Sakura Finetek, Zoeterwoude, The Netherlands), chilled in liquid nitrogen and stored at -80°C. For 
histochemical studies, coronal brain sections were made at 10-μm intervals.
Histology and ImmunohistochemistryThe gross morphology of the tumors was estimated after staining the coronal brain sections with 
hematoxylin and eosin (H&E). Immunohistochemical staining was performed with mouse-anti-rat monoclonal antibodies directed against CD45 (diluted 1/500), CD8a (1/600), and CD4 (diluted 1/100; both 
from Becton-Dickinson, Heidelberg, Germany), ED1 (1/500; Acris, Hiddenhausen, Germany), and CD11b (1/800; Serotec, Düsseldorf, Germany). Subsequently tissues were reacted with the secondary biotinylated rat-absorbed horse-anti-mouse antibodies, followed by avidin/biotinyl-peroxidase complexes (Vector Laboratories, Burlingame, CA, USA). Next, a diaminobenzidine-glucose oxidase technique was applied for immunoperoxidase labeling. Finally, sections were counterstained with hematoxylin. Omission of primary antibodies in control experiments resulted in the expected absence of any cellular labeling.
Data analysis
Descriptive results of tumor volumes in the 9L- and the 9L+HISE groups were presented as box plots using median, minimum, maximum, and both quartiles. Statistical differences between the groups were determined by the Wilcoxon rank sum test, and a P value < .05 was considered statistically significant. Survival times of the animals in both groups were obtained by Kaplan-Meier-estimates, and differences between survival curves were calculated using the Log-rank test, considering again P< .05 statistically 
significant. Statistical analysis was performed using SPSS 17 software.
Results
HISE-mediated oncolysis was ineffective in vitro Incubation of 105/ml 9L cells in DMEM with or without concomitant incubation with 105/ml HISE particles resulted in a tenfold increase in cell number after 7 days to 106/ml 
in either case. Even by adding 6x107/ml HISE particles, although outnumbering the HISE 
to 9L-ratio of 1:1 used in the animal experiments by 100x, gliosarcoma cells had tripled in number after 7 days. Therefore, in vitro-toxicity of HISE as used for the i.c. injection could be ruled out.
Heat-inactivated staphylococci delayed tumor growth and prolonged survival All animals tolerated the surgical procedure well, without postoperative neurological abnormalities, weight loss or infectious complications. Stereotactic implantation of 105 9L 
cells in 25μl PBS into the right striatum resulted in gliosarcoma formation in all (n=6) Wistar 
rats at the site of the implantation, whereas in only 9 of 12 animals receiving additional 105 
HISE particles an intracerebral tumor could be confirmed by MRI. 
Survival times differed markedly between both groups. Animals in the 9L-group died 
after a mean time of 17.8 d [median 18 d, range15-20 d]. In the HISE-treated group, 8 out 
of 9 animals that had developed gliosarcomas also died of the tumor burden, but showed 
a significant increase in average survival to 24.1 d [median 23 d, range 19-35 d] (Fig. 1). 
However, in one animal of the HISE-group, MRI demonstrated the formation of a mass within 
the right striatum, but after having reached its peak volume at day 19 it gradually regressed completely (Fig. 5A). Tumor volumes in both groups could be statistically compared exclusively at day 
13, since 5 out of 6 rats in the 9L-group had already died at the time of the follow-up 
MRI examination at day 19. Tumor growth was delayed in the HISE-treated rats, which 
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demonstrated a median mass volume of 60 µl (average: 77.8 µl) at day 13, in comparison 
to 90.5 µl (average: 109.3 µl) in untreated animals. However, the growth retardation in the 
HISE-group was not statistically significant (Fig. 2). At day 19, the median tumor volume in 
the latter group was 171 µl (average: 184.6 µl), whereas the mass of the remaining animal 
in the 9L-group was 305 µl. In control animals injected with 25 μl PBS, no intracerebral abnormalities apart from a circumscribed edema or scar formation along the needle track could be demonstrated on MRI (data not shown).
Naïve endogenous cellular immune reaction was inefficient to effectively restrain 9L 
gliosarcoma growth
Animals exclusively injected with 9L cells developed gliosarcomas appearing on MRI as well demarcated lesions with a distinct and homogeneous gadolinium enhancement 
(Fig. 3A). Histopathological examination revealed the tumors as round, monomorphic 
and sharply delineated masses with little invasion into the contiguous brain (Fig. 3B). The tumors were hypercellular and composed of spindle-shaped cells of a sarcomatoid 
phenotype with pleomorphic nuclei and numerous mitotic figures (Fig. 3C). Immunolabeling 
revealed an infiltration of scattered ED1+ activated macrophages, most of them localized within the outer regions of the mass, but hardly found in the adjacent brain parenchyma 
(Fig. 3D). Loosely assembled CD8a+ lymphocytes, mainly representing cytotoxic T-cells, could be observed especially at the tumor border and to a lesser extent within the mass, thus 
overlapping with the distribution of the activated macrophages (Fig. 3E). On the other hand, CD4+ T-lymphocytes were scattered throughout the whole lesions, in part accumulating in 
small clusters (Fig. 3F). In 2 of the 6 gliosarcomas of the 9L-group, small necrotic areas were present in the center of the lesions. However, no increase in the cellular immune reaction 
could be observed within or adjacent to these regions. In the 9L group, the impact of anti-
tumor immune response apparently did not exert any significant oncolytic potential, since 
no tumor regression could be observed despite the presence of ED1+ and CD4+/ CD8a+ cells.
Control animals injected with PBS showed a hardly discernible cellular infiltration 
directly adjacent to the needle track consisting merely of some loosely arranged ED1+ macrophages (data not shown).
Fig. 1. Kaplan-Meier estimate showing 
prolonged survival time of 9L gliosarcoma bearing experimental animals after synchronous inoculation of heat-inactivated S. epidermidis (HISE) (n=9) in contrast to control animals (n=6) (P < .001, log-rank-test).
Fig. 2. Box plots comparing tumor volumes of 
naïve 9L gliosarcoma and after concomitant HISE 
treatment at 13 days. Although median values in 
the HISE-treated animals were lower than those in 
controls, the difference was not significant between both groups (P = .145, Wilcoxon-test).
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HISE treatment led to a distinct activation of immune response and oncolysis
In HISE-treated animals, MRI showed a clearly reduced contrast enhancement of the 
lesions in comparison to the 9L-group at 13d in 5 of 9 tumor-bearing animals. At day 19, 
the pattern of gadolinium uptake of the masses was low in all animals of the HISE-group, 
either occurring as a homogeneously poor uptake (n=3), as a patchy enhancement (n=2), or 
as a ringwall enhancement with a central sparing (n=4) (Fig. 4A). HE-staining revealed an extensive oncolysis of the central mass in 4 brains with residual tumor remaining mainly at the periphery (Fig. 4B), and large-scale but less coalescing necrotic regions in the center of the gliosarcomas in another 2 cases. Three tumors showed only minor regressive changes. Hence, a considerable central eradication of the malignancy was observed in two thirds of 
the HISE-treated animals. At higher magnification, the oncolytic areas showed a mesh-like 
infiltration of variously shaped mononuclear cells and cellular debris, whereas neutrophilic granulocytes and tumor cells were virtually absent (Fig. 4C). Immunohistochemical staining 
confirmed an extensive peri- and intratumoral immune response in animals exhibiting 
central oncolysis. Numerous macrophages surrounded the tumor, distinctly infiltrating the solid portions and forming a dense ribbon around the oncolytic core (Fig. 4D). Moreover, the reticulated matrix within the necrotic center was also extensively interspersed by numerous 
macrophages (Fig. 4E). Cytotoxic T-lymphocytes were more numerous than macrophages and displayed a different spatial arrangement as they embanked at the outer tumor margins (Fig. 4F). However, they occurred less frequently within the inner solid portions and were 
Fig. 3. Morphological and im-munological characteristics of 
intracerebral 9L gliosarcoma in Wistar rats. MRI depicts the tumor as a solid mass (ar-rowheads) with an intense and almost homogeneous contrast enhancement (A). Representa-
tive HE-staining demonstrates a well-delineated lesion (ar-rowheads) with a compact ar-rangement (B), consisting of pleomorphic tumor cells with 
numerous mitotic figures (C). Immunohistological assess-ment of immune cell response 
reveals a minor infiltration by 
ED1+ macrophages and CD8a+ cytotoxic T-lymphocytes, both mainly localized at the out-er regions of the tumor but scarcely outside the lesion 
(D,E), and by scattered CD4+ T-
lymphocytes (F). D-F: immun-
operoxidase staining dark, HE- counterstaining. Scale bars in-
dicate 500 μm (B), 50 μm (C); 
and 200 μm (D,E, and F). Origi-
nal magnification x2.5 (B), x40 
(C) and x10 (D,E, and F).
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completely missing in the central oncoloytic region (Fig. 4G). CD4+ T-lymphocytes were crowding in peripheral areas of the gliosarcoma more extensively than cytotoxic T-cells (Fig. 4H), thereby, as macrophages, dissociating the reticulated architecture of the necrotic core (Fig. 4I). 
The considerable reinforcement of the cellular immune reaction resulting from HISE treatment led to an extensive oncolysis of the lesions in most animals. In one case it even resulted in a complete regression of the tumor. After rapid growth of the malignancy featuring 
an inhomogeneous contrast enhancement at day 19, it gradually regressed, accompanied by a decreasing gadolinium uptake, and ultimately resulted in a hypointense porencephalic 
defect (Fig. 5A). H&E-stained sections of this region disclosed brain tissue with a gliotic border encasing a spongy matrix traversed by large caliber vessels and numerous rounded 
cells (Fig. 5B), at a higher magnification clearly discernible as ochreous foamy macrophages (Fig. 5C), whereas gliosarcoma cells were absent. 
Fig. 4. Effects of HISE on 9L gliosarcoma growth. Serial MRIs from days 13 to 32 show a diminished gadolinium uptake of the early lesions in contrast to the controls, and a central sparing with a ringwall 
enhancement in the later stages of tumor progress (A). Correspondingly, HE-staining demonstrates a marked regression of the central mass with only small marginated tumor remnants left (arrows) (B). The reticulated matrix inside the lesion consists mainly of different mononuclear cells (closed arrows) intermingled with cellular debris (open arrows), whereas tumor cells are virtually absent in this region 
(C). Immunohistochemical analysis reveals a marked infiltration of ED1+ macrophages surrounding and 
infiltrating the marginated tumor, assembling around the oncolytic center like a palisade (arrows) (D), 
and extensively dissociating the reticulated core of the lesion (E). Infiltration by CD8a+ cytotoxic T-cells is even more pronounced at the outer margins of the residual tumor (arrows) (F), but is almost completely 
lacking within its necrotic core (G). Moreover, a massive embankment-like infiltration of the peripheral lesion by CD4+ T-lymphocytes (arrows) could be observed (H), that are also disseminated within the central 
oncolysis (I). D-I: immunoperoxidase staining dark, HE- counterstaining. Scale bars indicate 500 μm (B), 50 
μm (C,E,G, and I); and 200 μm (D,F, and H). Original magnification x2.5 (B), x40 (C,E,G, and I) and x10 (D,F, and H).
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DiscussionOur study provides a strong evidence for an immune-mediated antitumor effect of 
HISE leading to prolonged survival and even cure from experimental 9L gliosarcoma. The common mechanism of action of such immunostimulatory adjuvants (ISA) like inactivated whole bacteria such as S. epidermidis [19] or Bacillus Calmette-Guérin [20], bacterial cell-wall 
peptides [21-23], or synthetic molecules like imiquimod [24, 25] is the activation of Toll-like receptors, and the subsequent attraction and stimulation of antigen-presenting cells resulting in selective lysis of glioma cells. 
Once recruited to the site of the tumor in the 9L animal model, the individual leukocyte populations might inhibit gliosarcoma growth by different mechanisms. CD8a+ cells, mainly representing cytotoxic T lymphocytes (CTLs) that can directly lyse 
tumor cells, extensively infiltrated the proliferating parts of the tumor while completely sparing the central necrosis, indicating their attraction by viable malignant cells. Since 
we demonstrated recently that the widespread infiltration of CTLs after i.c. HISE injection 
reached its peak on day 4 and fell off thereafter [19], we hypothesize that only the initial 
steps of the cytotoxic response were triggered by HISE. The sustained trafficking of CTLs was 
possibly due to their specific targeting of tumor-associated antigens, probably after T-cell priming and clonal expansion in CNS-draining lymph nodes and subsequent homing back 
to the site of the antigenic threat in the brain [26]. Thus, HISE might act as a potent initiator 
for an effective homing of tumoricidal CTLs to the 9L gliosarcoma resulting in an extensive 
oncolysis. In contrast, 9L gliosarcoma without the adjunct of HISE failed to recruit significant numbers of CD8a+ cells to the tumor site. Indeed, effective eradication of malignant glioma is particularly dependent on a powerful CTL response, and a mathematical model demonstrated that several adoptive immunotherapy trials presumably failed because the number of CTLs administered was too small to overcome the immunosuppressive counterattack of the tumor [27]. 
Fig. 5. Complete regres-
sion of a 9L gliosarcoma 
after concomitant HISE treatment. Serial MRI sec-tions clearly demonstrate a progressive increase 
in tumor size at first, fol-lowed by a gradual disap-pearance of the contrast-enhancing mass lesion and a parenchymal defect 
in the final state (A). Histo-
logical sections after HE-staining demonstrate the defect zone composed of a loosely reticulated, vas-cularized (closed arrows) tissue surrounded by a gliotic scar (open arrows) (B) and crowded with big foamy macrophages (ar-rows) (C). Scale bars in-
dicate 200 μm (B); and 50 
μm (C). Original magni-
fication x 10 (B) and x40 (C).
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The massive accumulation of macrophages adjacent to and dissociating the whole 
gliosarcoma was at least in part induced by HISE, since we could demonstrate macrophages 
as predominating leukocytes from day 4 on after its i.c. administration [19]. Besides, macrophages were presumably attracted by the necrotic remnants in the center of the lesions, acting there as scavengers like in the animal cured from the gliosarcoma, where they were still detectable in the porencephalic defect. As their putative key function macrophages act as antigen-presenting cells (APCs) to CTLs and provide co-stimulatory signals, triggering proliferation and differentiation of CD8+ T-cells [28]. Moreover, perivascular APCs mediate the migration of CD4+ T- cells across the blood-brain barrier [29] and are mandatory for 
antigen-specific reactivation of effector T-cells and their persistence within the brain [30], thus illustrating their central role during establishment of a tumor-defensive immune 
network. However, it remains elusive to what extent these tumor infiltrating macrophages 
are blood-derived or represent activated microglia, since ED1 stains both and there is no 
more specific marker.As was observed with CTLs, the transmigration of CD4+ T- cells into the HISE-treated gliosarcoma is supposed to be initiated by the bacterial epitopes, since naïve tumors showed only minor CD4+ cell infiltration. Their distinct and sustained recruitment is indeed most 
likely costimulated by tumor-associated antigens, as mere i.c. HISE application resulted 
in a persistent, but only scattered infiltration as demonstrated recently [19]. To activate a CD4+ response, tumor antigen epitopes must be presented concomitantly with an MHC Class II complex, e.g. on macrophages as APCs. Once activated, CD4+ lymphocytes enhance 
CTL activation [31] and recruit additional macrophages. On the other hand, an impaired CD4+ T-cell response in the brain would impede CD8+ T-cells from developing into memory 
cells [32]. Finally, the T-helper (Th) 1 subset of activated CD4+ T-lymphocytes is capable to 
directly kill malignant cells in several tumors outside the CNS [33], but these direct oncolytic effects are poorly characterized in malignant gliomas. 
The extensive immune cell activation and retainment after HISE treatment and the 
effective antitumor response induced in two thirds of the animals in the HISE-group is likely 
a two-stage process. Initially, HISE effectively recruits macrophages, CTLs and CD4+ T-cells, 
as previously demonstrated [19]. Due to absent diffusion capacity and adhesive properties 
of inactivated staphylococci, the inflammatory reaction keeps confined to the HISE-tumor cell deposit. Afterwards, the already abundantly recruited systemic immune cells cross-react with tumor-associated epitopes, that by itself would be unable to attract a substantial number of T-lymphocytes or macrophages. However, tumor growth has been capable of 
overcoming the inflammatory attack, since in every fourth case oncolysis and immune cell 
infiltration was poor despite HISE application. On the other hand, the missing development of 
a tumor in some HISE-treated animals was presumably caused by an immediate tumoricidal 
neuroinflammatory response, since toxic effects of HISE in vitro could be ruled out. 
The 9L gliosarcoma model has been the most extensively used experimental rat brain 
tumor model [34] and has also been well characterized for its applicability in allogeneic 
Wistar rats [35]. The 9L cell line was deliberately chosen for the purpose of our experiments 
for two reasons. First, the 9L gliosarcoma has been shown to secrete the cytokine TGF-beta 
2 [36] and in this regard simulate the tumor-induced local immunosuppression of human 
glioblastoma. Second, 9L cells produce sharply delineated tumors and thereby allow a more reliable morphometrical evaluation by MRI than the utilization of a tumor cell line 
generating an ill-defined, infiltrative mass [37]. In conclusion, by eradicating the proliferating properties of staphylococci by heat-inactivation, the potential disastrous effects of a postoperative infection could be transformed 
into a novel immunotherapeutic approach for high-grade glioma. HISE treatment markedly enhanced the number of CTLs, macrophages and CD4+ T-cells at the tumor site and reduced 
brain tumor growth. Our promising results demonstrate for the first time that inactivated bacteria may be utilized as potent immunostimulatory adjuvants in intracranial tumor therapy. Given the great diversity of bacteria and their different immunomodulatory                 
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properties, our findings might stimulate further investigations to explore their therapeutic potential in the treatment of high-grade glioma.
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